在HR+早期乳腺癌中与更年期相关的副作用:从临床实践的见解
Marija Dimitrijevic1, Marina Calamac1, Ognjen Djurmez1
1Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Therapeutic advances in medical oncology
|August 4, 2025
概括
卵巢功能抑制 (OFS) 和内分泌疗法 (ET) 在患有早期乳腺癌的年轻女性中会引起热和睡眠问题等副作用. 这些症状随着时间的推移而恶化,特别是在年轻患者中.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 生活质量研究 研究 生命质量研究
背景情况:
- 卵巢功能抑制 (OFS) 和过早更年期对被诊断患有激素受体阳性早期乳腺癌 (HR+ eBC) 的年轻女性的生活质量产生重大影响.
- 了解OFS和内分泌疗法 (ET) 的副作用概况对于管理HR+eBC在这个人口群体中至关重要.
研究的目的:
- 为了回顾性地分析在被诊断为HR+eBC的年轻女性中与OFS和ET相关的最常见的副作用.
- 评估36个月期间这些副作用的频率和时间动态.
主要方法:
- 进行了一项回顾性队列研究,涉及100名HR+eBC患者接受OFS和ET.
- 在预先定义的时间点 (基线至36个月) 分析了超过10%的患者出现的副作用.
- 数据按年龄 (<= 40 vs. > 40岁) 和先前化疗 (CT) 状态分层.
主要成果:
- 血管运动症状 (发热,夜间出汗) 是最常见的副作用,在前6个月内达到顶峰.
- 较年轻的女性 (<40岁) 报告说,与老年女性相比,夜间出汗和睡眠障碍明显增加.
- 在没有接受CT治疗的患者中,热很常见,夜间出汗在6个月后显著差异.
结论:
- 接受OFS和ET的HR+eBC的年轻女性经常经历副作用,包括发热,夜间出汗,睡眠障碍和焦虑.
- 这些症状往往会随着时间的推移而恶化,在30个月的随访后显著增加.
- 年龄和先前的化疗影响了特定副作用的流行率和模式.
相关概念视频
01:28Menopause
251
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
251
01:24Disorders of the Female Reproductive System
492
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
492
01:21Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455
01:22Hormonal Regulation of the Menstrual Cycle
700
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
700
01:12Hazard Ratio
247
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
247
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K